Literature DB >> 32515043

Annual decline in β-cell function in patients with type 2 diabetes in China.

Zhenxiu Gao1,2, Wei Yan1, Zhaohui Fang3, Zongjun Zhang1, Li Yuan4, Xiaoyun Wang5, Zhumin Jia6, Yuanyuan Zhu2, Joshua D Miller7, Xiaodan Yuan1, Fan Li8, Qingqing Lou1.   

Abstract

BACKGROUND: The aim of this study was to investigate the annual decline of β-cell function correlated with disease duration in patients with type 2 diabetes in China.
METHODS: This cross-sectional study included 4792 adults with type 2 diabetes who were recruited from four university hospital diabetes clinics between April 2018 and November 2018. Baseline data were collected from electric medical records. Participants were divided into 21 groups with 1-year diabetes duration interval to assess the decline rate of β-cell function. Homeostatic model assessment model (HOMA 2) model was applied to assess β-cell function. Multiple linear regression model was used to evaluate the association between biochemical and clinical variables and β-cell function.
RESULTS: In Chinese patients with type 2 diabetes, β-cell function declined by 2% annually. Using angiotensin receptor blockade (ARB) (β = .048; P = .011), metformin (β = .138; P = .021), or insulin (β = .142; P = .018) was associated with increased β-cell function. However, increased BMI (β = -.215; P = .022), alcohol consumption (β = -.331; P < .001), haemoglobin A1c (β = -.104; P = .027), or increased diabetes duration (β = -.183; P = .003) was significantly and negatively associated with β-cell function.
CONCLUSIONS: We determined that the annual rate of the β-cell function decline was 2% in patients with type 2 diabetes in China. Moreover, we confirmed a positive relationship between ARB treatment and β-cell function, while BMI and alcohol consumption were significantly and negatively associated with the β-cell function.
© 2020 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2020        PMID: 32515043     DOI: 10.1002/dmrr.3364

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  3 in total

1.  Basal Insulin Reduces Glucose Variability and Hypoglycaemia Compared to Premixed Insulin in Type 2 Diabetes Patients: A Study Based on Continuous Glucose Monitoring Systems.

Authors:  Huiying Wang; Yunting Zhou; Yuming Wang; Tingting Cai; Yun Hu; Ting Jing; Bo Ding; Xiaofei Su; Huiqin Li; Jianhua Ma
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-27       Impact factor: 6.055

2.  Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: A population-based observational study.

Authors:  Calvin Ke; Thérèse A Stukel; Baiju R Shah; Eric Lau; Ronald C Ma; Wing-Yee So; Alice P Kong; Elaine Chow; Juliana C N Chan; Andrea Luk
Journal:  PLoS Med       Date:  2020-09-18       Impact factor: 11.069

3.  Case Report: A Chinese Family of Woodhouse-Sakati Syndrome With Diabetes Mellitus, With a Novel Biallelic Deletion Mutation of the DCAF17 Gene.

Authors:  Min Zhou; Ningjie Shi; Juan Zheng; Yang Chen; Siqi Wang; Kangli Xiao; Zhenhai Cui; Kangli Qiu; Feng Zhu; Huiqing Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-23       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.